Eszlari, N
Kovacs, D
Petschner, P
Pap, D
Gonda, X
Elliott, R
Anderson, I M
Deakin, J F W
Bagdy, G
Juhasz, G
Article History
Received: 14 July 2015
Revised: 14 December 2015
Accepted: 14 January 2016
First Online: 1 March 2016
Competing interests
: JFWD has variously performed consultancy, speaking engagements and research for Bristol-Myers Squibb, AstraZeneca, Eli Lilly, Schering Plough, Janssen-Cilag and Servier (all fees are paid to the University of Manchester to reimburse them for the time taken); he also has share options in P1vital. IMA has received consultancy fees from Servier, Alkermes, Lundbeck/Otsuka and Janssen, an honorarium for speaking from Lundbeck and grant support from Servier and AstraZeneca. RE has received consultancy fees from Cambridge Cognition and P1vital. The remaining authors declare no conflict of interest.